Idec moves on FDA letter

IDPH was up $6.84 (15%) to $51.94 on Friday after word got out that it had received a complete review letter from the FDA for its BLA for Zevalin ibritumomab tiuxetan. In January, the agency accepted for filing IDPH's BLA for Zevalin radiolabeled antibody to treat low grade or follicular, relapsed or refractory, CD20-positive, B cell non-Hodgkin's lymphoma (NHL), and follicular NHL that is refractory to IDPH's Rituxan rituximab anti- CD20 antibody. The company would not provide any further comment. ...